1Gerhard RT, Perras JP, Sevin BU, et al. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphatc chemoscnsitivity Assay[J]. Am J Obstet Gynecol, 1991,165(2) :245.
2Unteh M, Sevin BU, Perras JP, et al. Evalueation of paelitaxel (Taxol), eisplatin and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay[J]. Gynecol Oncol, 1994,53( 1 ) :44.
3Sevin BU, Perras JP. Tumor heterogeneity and in vitro ehemosensitivity testing in ovarian eancer[J]. Am J Obstet Gynecol, 1997,176(4.) :759.
4Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate lumiscence assay: clinical correlation for cisplatin Resistance of ovarian carcinoma [J]. Cancer Res, 1995,55 ( 15 ) : 5276.
5Ng TY, Ngan HY, Cheng DK, et aI. Clinical applicability of the ATP cell viabilky assay as a predictor of ehemoresponse in platinum-resistant epithelial ovarian cancer using non surgical tumor cell samples [J]. Gynecol Oncol, 2000,76 (3) : 405.
6Mercer SJ ,Somers SS,Knight LA ,et al. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma [J]. Anticancer Drugs,2003,14(6) :397.
7Whitehouse PA, Knight LA, Di Nicolantonio F, et al. Heterogeneity of chemosensitivity of coIorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA) [J]. Anticancer Drugs, 2003, 14(6) : 369.
8Kurbacher CM,Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer[J]. Anticancer Drugs, 1998,9( 1 ) : 51.
10Breidenlaacla M, Rein DT, Mallmann P, et al. Individualized longterm chemotherapy for recurrent ovarian cancer after failing high-dose treatment [J]. Anticancer Drugs, 2002,13 (2) : 173.
